Thus, the Libredecov project is working on the development of a 3D printed mask (additive manufacturing) with filters for the safe sampling and rapid analysis of viruses, which is a simple sampling procedure for use by non-specialized personnel. Biomedal's objective is to position itself in easy-to-use tests close to the patient and for sale in pharmacies.

On the other hand, he is working on a semi-quantitative rapid laboratory test to determine the quality of the antigenic response to coronavirus in infected or eventually vaccinated individuals. This test, which follows a fluorescence immunochromatography methodology, will use a reader that will quantify the results obtained. Finally, it explores a system for rapid in situ detection of coronavirus-contaminated surfaces by LTF or immunochromatography. Immunochromatography is one of the most modern immunodiagnostic techniques whose advantages are the simplicity and speed of the test.

Biomedal has previous experience in the development and selection of rapid serological methods to detect gluten or COVID-19 exposure from different manufacturers, and has coordinated clinical studies to evaluate their reliability and clinical utility.

About Biomedal

Biomedal S.L. is a private biotechnology company located in Seville with 20 years of experience in the research, development, production and commercialization of innovative biotechnological products to be used as tools by different industries, such as pharmaceutical and health. Thus, it has developed methods for the diagnosis of human diseases and systems for testing to ensure the presence or absence of toxic allergens in food by certified analytical methods. It also develops basic and applied research in a number of sectors, using recombinant protein expression and purification systems, microbial cultures, and other supports, reagents or systems for the study, analysis or engineering of microorganisms.

Biomedal has exported products and licenses to more than 50 countries, with more than 2,400 customers in the five continents and maintains close collaborations with excellent scientific groups belonging to public and private institutions for the development of innovative biotechnological tools.